New treatment modalities in advanced thyroid cancer

被引：67

作者：

Kapiteijn, E. ^{[1
]}

Schneider, T. C. ^{[1
]}

Morreau, H. ^{[2
]}

Gelderblom, H. ^{[1
]}

Nortier, J. W. R. ^{[1
]}

Smit, J. W. A. ^{[3
]}

机构：

[1] Leiden Univ, Dept Clin Oncol, Med Ctr, NL-2300 RC Leiden, Netherlands

[2] Leiden Univ, Dept Pathol, Med Ctr, NL-2300 RC Leiden, Netherlands

[3] Leiden Univ, Dept Endocrinol & Metab Dis, Med Ctr, NL-2300 RC Leiden, Netherlands

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷 / 01期

关键词：

molecular pathogenesis; new treatment modalities; thyroid cancer; PHASE-II TRIAL; RECEPTOR RADIONUCLIDE THERAPY; HISTONE DEACETYLASE INHIBITOR; GROWTH-FACTOR-RECEPTOR; REDIFFERENTIATION THERAPY; PROGNOSTIC VALUE; BRAF MUTATION; RADIOIODINE THERAPY; SIGNALING PATHWAY; GENE METHYLATION;

D O I：

10.1093/annonc/mdr117

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Thyroid cancer is a heterogeneous disease that is classified into differentiated thyroid carcinoma (DTC), undifferentiated/anaplastic thyroid carcinoma (ATC) and medullary thyroid carcinoma. Results of conventional treatment modalities in advanced thyroid cancer have been disappointing and therefore, new therapies are needed. Methods: We searched PubMed, The Cochrane Library, Medline and EMBASE databases and abstracts published in annual proceedings for new treatment modalities in advanced thyroid cancer. We also searched for ongoing trials in www.clinicaltrials.gov Results: Six phase I, 17 phase II and 1 phase III trials with tyrosine kinase inhibitors were carried out. We found 2 pilot studies and 11 phase II trials with redifferentiation therapies, mainly in DTC. For antiproliferative approaches, three phase I and four phase II trials were found. Immunomodulatory gene therapy was tested in a pilot study in ATC patients. Two phase II trials were carried out with immunotherapy. One phase I and nine phase II trials were found with radionucleotide therapy in patients with DTC. Conclusion: The developments in the treatment of advanced thyroid cancer are intriguing. Future trials should aim at combinations of targeted agents with or without other treatment modalities, and will hopefully contribute to further improvement of outcomes.

引用

页码：10 / 18

页数：9

共 106 条

[51]

LUCAS AS, 2010, J CLIN ONCOL S, V28, pS15

[52] Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells [J].

Marsee, DK ;

Venkateswaran, A ;

Tao, HY ;

Vadysirisack, D ;

Zhang, ZX ;

Vandre, DD ;

Jhiang, SM .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (42) :43990-43997

[53] Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase [J].

Matsui, Junji ;

Funahashi, Yasuhiro ;

Uenaka, Toshimitsu ;

Watanabe, Tatsuo ;

Tsuruoka, Akihiko ;

Asada, Makoto .

CLINICAL CANCER RESEARCH, 2008, 14 (17) :5459-5465

[54] E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition [J].

Matsui, Junji ;

Yamamoto, Yuji ;

Funahashi, Yasuhiro ;

Tsuruoka, Akihiko ;

Watanabe, Tatsuo ;

Wakabayashi, Toshiaki ;

Uenaka, Toshimitsu ;

Asada, Makoto .

INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (03) :664-671

[55] Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro [J].

Mitsiades, Constantine S. ;

McMillin, Douglas ;

Kotoula, Vassiliki ;

Poulaki, Vassiliki ;

McMullan, Ciaran ;

Negri, Joseph ;

Fanourakis, Galinos ;

Tseleni-Balafouta, Sophia ;

Ain, Kenneth B. ;

Mitsiades, Nicholas .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (10) :4013-4021

[56] Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells [J].

Mitsutake, N ;

Knauf, JA ;

Mitsutake, S ;

Mesa, C ;

Zhang, L ;

Fagin, JA .

CANCER RESEARCH, 2005, 65 (06) :2465-2473

[57] Increased expression of phosphorylated p70S6 kinase and akt in papillary thyroid cancer tissues [J].

Miyakawa, M ;

Tsushima, T ;

Murakami, H ;

Wakai, K ;

Isozaki, O ;

Takano, K .

ENDOCRINE JOURNAL, 2003, 50 (01) :77-83

[58] Phase II study of celecoxib in metastatic differentiated thyroid carcinoma [J].

Mrozek, Ewa ;

Kloos, Richard T. ;

Ringel, Matthew D. ;

Kresty, Laura ;

Snider, Paulette ;

Arbogast, Daria ;

Kies, Merrill ;

Munden, Reginald ;

Busaidy, Naifa ;

Klein, Mary Jean ;

Sherman, Steven I. ;

Shah, Manisha H. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06) :2201-2204

[59] Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer [J].

Papewalis, Claudia ;

Wuttke, Margret ;

Seissler, Jochen ;

Meyer, Yvonne ;

Kessler, Caroline ;

Jacobs, Benedikt ;

Ullrich, Evelyn ;

Willenberg, Holger S. ;

Schinner, Sven ;

Baehring, Thomas ;

Scherbaum, Werner A. ;

Schott, Matthias .

CLINICAL CANCER RESEARCH, 2008, 14 (13) :4298-4305

[60] A phase II study of gefitinib in patients with advanced thyroid cancer [J].

Pennell, Nathan A. ;

Daniels, Gilbert H. ;

Haddad, Robert I. ;

Ross, Douglas S. ;

Evans, Tracey ;

Wirth, Lori J. ;

Fidias, Panos H. ;

Temel, Jennifer S. ;

Gurubhagavatula, Sarada ;

Heist, Rebecca Suk ;

Clark, John R. ;

Lynch, Thomas J. .

THYROID, 2008, 18 (03) :317-323

← 1 2 3 4 5 6 7 8 9 10 →